Bedside testing of CYP2C19 gene for treatment of patients with PCI with antiplatelet therapy.
Abdullah M Al-RubaishFahad A Al-MuhannaAbdullah M AlshehriMohammed A Al-MansoriRudaynah A AlaliRania M KhalilKhalid A Al FaraidyCyril CyrusMohammed M SuliemanChittibabu VatteDaniel M F ClaassensJurriën M Ten BergFolkert W AsselbergsAmein K Al-AliPublished in: BMC cardiovascular disorders (2020)
Trial registration name is "Bedside Testing of CYP2C19 Gene for Treatment of Patients with PCI with Antiplatelet Therapy" (number NCT01823185) retrospectively registered with clinicaltrials.gov on April 4, 2013. This trial is currently at the patient recruitment stage.
Keyphrases
- antiplatelet therapy
- percutaneous coronary intervention
- acute coronary syndrome
- st segment elevation myocardial infarction
- acute myocardial infarction
- coronary artery disease
- clinical trial
- study protocol
- copy number
- st elevation myocardial infarction
- genome wide
- phase ii
- phase iii
- atrial fibrillation
- randomized controlled trial
- heart failure
- combination therapy
- dna methylation
- case report
- left ventricular
- replacement therapy
- genome wide identification
- open label
- double blind